CTOs on the Move

STI Technologies

www.smartsti.com

 
STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.smartsti.com
  • 38 Solutions Drive Suite 200

    Halifax, NS CAN B3S 0H1
  • Phone: 902.450.5500

Executives

Name Title Contact Details

Similar Companies

Centaur Pharmaceuticals

Centaur Pharmaceuticals is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.

Raland Technologies

Raland Technologies is a Fairport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KidMed VA

Get expert pediatric urgent care for your child. Find the KidMed location nearest you, or learn more about what makes us the regions leading choice.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.